LLA vs. DXRX, AGL, YGEN, ABDX, GDR, VRCI, PRM, GENI, IDHC, and LLAI
Should you be buying LLA.L,0P0001T9GN,0 stock or one of its competitors? The main competitors of LLA.L,0P0001T9GN,0 include Diaceutics (DXRX), ANGLE (AGL), Yourgene Health (YGEN), Abingdon Health (ABDX), genedrive (GDR), Verici Dx (VRCI), Proteome Sciences (PRM), GENinCode (GENI), Integrated Diagnostics (IDHC), and LungLife AI (LLAI). These companies are all part of the "diagnostics & research" industry.
LLA.L,0P0001T9GN,0 vs.
Diaceutics (LON:DXRX) and LLA.L,0P0001T9GN,0 (LON:LLA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, community ranking, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.
52.4% of Diaceutics shares are owned by institutional investors. Comparatively, 5.4% of LLA.L,0P0001T9GN,0 shares are owned by institutional investors. 34.3% of Diaceutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, Diaceutics' average media sentiment score of 0.00 equaled LLA.L,0P0001T9GN,0'saverage media sentiment score.
Diaceutics received 12 more outperform votes than LLA.L,0P0001T9GN,0 when rated by MarketBeat users.
Diaceutics has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Comparatively, LLA.L,0P0001T9GN,0 has a beta of -0.3, meaning that its share price is 130% less volatile than the S&P 500.
Diaceutics presently has a consensus price target of GBX 160, indicating a potential upside of 31.69%. Given Diaceutics' higher probable upside, analysts plainly believe Diaceutics is more favorable than LLA.L,0P0001T9GN,0.
Diaceutics has higher revenue and earnings than LLA.L,0P0001T9GN,0. Diaceutics is trading at a lower price-to-earnings ratio than LLA.L,0P0001T9GN,0, indicating that it is currently the more affordable of the two stocks.
LLA.L,0P0001T9GN,0 has a net margin of 0.00% compared to Diaceutics' net margin of -10.90%. Diaceutics' return on equity of -7.13% beat LLA.L,0P0001T9GN,0's return on equity.
Summary
Diaceutics beats LLA.L,0P0001T9GN,0 on 11 of the 13 factors compared between the two stocks.
Get LLA.L,0P0001T9GN,0 News Delivered to You Automatically
Sign up to receive the latest news and ratings for LLA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
LLA.L,0P0001T9GN,0 Competitors List
Related Companies and Tools
This page (LON:LLA) was last updated on 11/2/2024 by MarketBeat.com Staff
